Company Overview
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -73.15% |
| 6 Months: | -18.45% |
| 3 Months: | -17.00% |
| 1 Month: | -18.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 75.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLTX MoonLake Immunotherapeutics PHARMA | 14.94 | -3.89 | $1.27B | 0.00% | -64.61% | -67.47% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -94.11K | -32.68M | -6.27M | -15.94M | -17.65M | -14.77M | -12.93M | -13.19M | -12.98M | -19.82M | -30.58M | -43.11M | -47.48M | -60.70M | -71.43M | -70.02M | -61.66M |
| Net Income | -76.29K | -32.69M | -6.29M | -15.88M | -12.12M | -10.11M | -9.00M | -10.14M | -9.43M | -13.67M | -24.27M | -35.39M | -39.94M | -55.22M | -69.73M | -69.71M | -61.80M |
| Diluted EPS | - | -2.90 | -2.63 | -3.17 | -0.34 | -0.27 | -0.23 | -0.23 | -0.18 | -0.22 | -0.39 | -0.56 | -0.63 | -0.87 | -1.10 | -0.98 | -0.84 |
| R&D Expense | - | 29.87M | 669.53K | 10.45M | 11.40M | 9.02M | 7.42M | 8.70M | 7.59M | 13.01M | 23.66M | 35.74M | 36.46M | 49.76M | 60.63M | 54.52M | 50.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -4.57M | -65.06M | -54.12M | -143.09M | -244.83M |
| Net Income | -4.54M | -49.97M | -36.01M | -118.94M | -227.32M |
| Diluted EPS | - | -1.70 | -0.73 | -1.89 | -3.53 |
| R&D Expense | - | 42.05M | 31.80M | 112.77M | 202.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 116.63M | - | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Total Equity | -2.52M | 106.51K | -11.65M | 48.90M | 495.68M | 446.82M | 304.48M |
| Cash & Equivalents | 1.34M | - | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Long Term Debt | - | - | - | - | - | 0 | 74.10M |
| Total Liabilities | 4.15M | - | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Current Liabilities | 125.18K | - | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -611.07K | -55.89M | -42.78M | -116.59M | -196.01M |
| Investing Cash Flow | - | -32.34M | -25.18M | -205.60M | 202.99M |
| Financing Cash Flow | -58.06K | 119.69M | 479.70M | 51.31M | 146.00M |
| Capital Expenditure | - | -16.01K | -284.00K | -520.00K | -35.00K |
| Free Cash Flow | - | -55.91M | -43.06M | -117.11M | -196.04M |
| Share Buybacks | - | 0 | 0 | 50 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | 39.0% | -102.2% | -7.3% | -26.6% | -74.7% |
| ROCE % | 40.1% | -94.0% | -10.5% | -31.4% | -64.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 18.80% | 16.00M | $198.26M |
| 2 | Deep Track Capital, Lp | 8.22% | 7.00M | $86.72M |
| 3 | T. Rowe Price Investment Management, Inc. | 5.03% | 4.28M | $53.04M |
| 4 | Shaw D.E. & Co., Inc. | 3.95% | 3.37M | $41.70M |
| 5 | Cormorant Asset Management, LP | 3.77% | 3.21M | $39.72M |
| 6 | Jupiter Topco LLC | 3.63% | 3.09M | $38.23M |
| 7 | Logos Global Management LP | 3.14% | 2.67M | $33.14M |
| 8 | Weiss Asset Management Lp | 3.03% | 2.58M | $31.99M |
| 9 | Citadel Advisors Llc | 2.32% | 1.97M | $24.44M |
| 10 | Two Sigma Investments, LP | 2.02% | 1.72M | $21.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLTX
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQnlIOGJJbzZZb002Mmxwc1pZZ3JNamJMZGg3OXpDYWNEOHFEVXZfNDY4LWMwRTdFMHBBSFdxXzBiSFAyRVFnQmg4a0NNd09fcGlJWEtHTVNlamNTU2ZxaWJ1N05rdHo2MlhJSDVEbERGdmFsQjRVMm02bGEwT2hHLUxzb3NnaDRjMThtR2…
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQaXRqR3daSy1QYlNrWm40RnVZeXVHanptTldNNFZvM2tSZjhmX1ZrQ3pHNTJaS2ZNb3Zfenc2cDVOd3djbHVhZzhpa0tZU3hVRmFwS2FwYi13OW9pYUxNNmtpWDFMTFdlQjA0MGExMHhFNWs0NlNLVm9LakwweTI4bWJYcWV4NzA2WFBkNT…
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOVkttWU9KWHY3OUJkNUszQkdvWFRuc29yUnlGU0hLR2Q5WE1oMDl5Q1NJZl8zTm5wZHBRZ29VOURvM0xUZ3dlVmdhTWkxcU0yYmdkNlZTdDZ3bGFfY3VQdU5PZjhBeW1SRWVJZlpaUTgzTUU5Z3UyckpSTTBSM2d6MmN3RE5uTG5HUWJJV2…
MoonLake reports positive Phase 3 PsA data and $537 million cash | MLTX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOOEVBeS0tdllsaThsRTUxZjN5SExoWE9jTkt6T1ZQUDJuMWYxRDllcVNEbWdFczVvQjQ0aHVoNEVpdXl4NlNZTkhObEdpNWo4UURRemlsazh6QTFWU2M5dTVNOHhnM25vTGhrWVBfUVMtQlNJY2RNbHhKc0pTdVl1c3FKcVZNZTk4Z1d0WV…
MLTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1GNTRMLTRTdXVCRVZfZlNBa0ZCcEQ3NXVIMHZEVTJBeXR2eENENV9UbU5TS2VQcGVVMHFKMW1hc2pnRWxOQkFqTzB5WGJZVHRMWlh3cDNPT18yWnpNMFlwOUREVDJDVmtpcmR5RjRFRWloek9USHB5YUNR?oc=5" target="_blank">MLT…
Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNY2gzeE15bERrQ0xjREFlMXB2Q19jVTQyZlJ3WXNZOGVQOXZPdkZ5YjJMUUdNdUtxTjVZY01ZVGliZ2MxOEFwWF9vVEtrcXp1dzdCd0FSYjdPSzQydnFjOHJwcW9zeHpNREc4RU13d2k4Z1luUGNabTZBemJ6b2hKYllYcHpqeTktSWp6dl…
MLTX — Frequently Asked Questions
What is the current share price of MoonLake Immunotherapeutics (MLTX)?
As of 2026-09-19 21:16 PDT, MoonLake Immunotherapeutics (MLTX) trades at $14.94 on NasdaqCM. Its 52-week range is $6.24 to $61.99.
What is the market capitalisation of MLTX?
MoonLake Immunotherapeutics (MLTX) has a market capitalisation of $1.27B on NasdaqCM.
What is the P/E ratio of MLTX?
MLTX trades at a trailing price-to-earnings (P/E) ratio of -3.89. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.42.
What is the return on equity (ROE) of MLTX?
MLTX has a return on equity (ROE) of -67.47%. Its return on capital employed (ROCE) is -64.61%.
Is MLTX a good stock to buy?
This page provides a data-driven analysis of MoonLake Immunotherapeutics (MLTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.